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Abstract  1 
Glioblastoma multiforme (GBM) is the most aggressive brain tumor and human T98G cells 2 
constitute a useful GBM model to evaluate chemotherapeutic agents. Modern life (shiftwork, 3 
jetlag, etc.) may cause circadian disorganization promoting higher cancer risk and metabolic 4 
disorders. Although little is known about the tumor-intrinsic circadian clock function, 5 
pharmacological modulation of circadian components may offer selective anticancer strategies. 6 
REV-ERBs are heme-binding circadian clock components acting as repressors of processes 7 
involved in tumorigenesis such as metabolism, proliferation and inflammation. A synthetic 8 
pyrrole derivative (SR9009) that acts as REV-ERBs specific agonists exhibits potent in vivo 9 
activity on metabolism and tumor cell viability. Here we investigated SR9009 effects on T98G 10 
cell viability, differential chemotherapy time responses and underlying metabolic processes 11 
(reactive oxygen species: ROS and lipid droplets: LD) and compared it with the proteasome 12 
inhibitor Bortezomib (BOR) treatment. SR9009-treated cells exhibited significant reduction in 13 
cell viability with consequences on cell cycle progression.  Dexamethasone (DEX) synchronized 14 
cells displayed differential time responses to SR9009 treatment with highest responses 18-30 h 15 
after synchronization. SR9009 treatment decreased ROS levels while BOR increased them. 16 
However, both treatments significantly increased LD levels whereas the combined treatment 17 
showed synergism between both drugs. In addition, we extended these studies to HepG2 cells 18 
which also showed a significant decrease in cell viability and ROS levels, and the increase in LD 19 
levels after SR9009 treatment. Our results suggest that the pharmacological modulation of the 20 
tumor intrinsic clock by REV-ERB agonists severely affects cell metabolism and promotes 21 




Summary statement 1 
T98G cells constitute a glioblastoma model to evaluate pharmacological modulation of 2 
tumor-intrinsic circadian clock components as anticancer strategies. Pyrrole derivatives 3 
(SR9009) acting as specific REV-ERBs agonists (circadian clock repressors) displayed 4 




Carcinogenesis is a complex and multi-etiological process resulting in the accumulation of 9 
genetic alterations primarily in genes involved in the regulation of signaling pathways relevant to 10 
the control of cell growth and division (reviewed in Hanahan and Weinberg, 2011). Neoplastic 11 
processes include a number of typical characteristics such as sustained proliferative activation, 12 
growth suppressor evasion, cell death resistance, replicative immortality, induction of 13 
angiogenesis, and invasiveness and metastasis, all of which are based on genome instability and 14 
inflammation. 15 
Under physiological conditions, circadian clocks are near 24-h endogenous oscillators that 16 
control a complex net of physiological and behavioral processes such as the daily sleep and wake 17 
cycle, body temperature, feeding behavior, hormone secretion, drug and xenobiotic metabolism, 18 
glucose homeostasis and cell cycle progression (Lowrey and Takahashi, 2004; Bell-Pedersen et 19 
al., 2005). At the cellular level, a redox / metabolic oscillator (R/MO) has been described to 20 
interact with the circadian molecular clock (Dibner and Schibler, 2015; Wagner et al., 2018); this 21 
R/MO has been shown to be ancestral and highly conserved through evolution [review in (Edgar 22 
et al., 2012)]. Taken together we may infer that the cellular clock that temporarily controls 23 
cellular processes is made up of a molecular clock (transcription/translation feedback loop) and a 24 
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R/MO. In mammals, disruption of circadian rhythms increases cancer incidence and metabolic 1 
disorders. Cell-autonomous clocks are composed of a transcription–translation-based feedback 2 
loop made up of a set of genes that include Clock (and its paralogue Npas2) and Bmal1 as 3 
activator components and  Per1, Per2, Cry1 and Cry2 as repressor components.(King et al., 4 
1997;  Gekakis et al., 1998). The entire cycle of transcription and translation takes approximately 5 
24 h to be completed. In addition, the CLOCK–BMAL1 complex may activate a second 6 
alternative cycle involving  the nuclear receptors REV-ERBα and REV-ERBβ which compete at 7 
the retinoic acid-related orphan receptor (ROR)- binding elements (ROREs) with the activators 8 
RORα, RORβ and RORγ (Preitner, Damiola, Luis-Lopez-Molina, et al., 2002; Sato et al., 2004; 9 
Zhang et al., 2015). The rhythmic expression of REV-ERBα/β leads to the repression of BMAL1 10 
and CLOCK, which in turn induces a rhythm in these genes that is in anti-phase with PER 11 
expression rhythms (Preitner, Damiola, Lopez-Molina, et al., 2002). In fact, REV-ERBs and 12 
RORs are crucial components of the circadian clock that links the core circadian oscillator to the 13 
regulation of clock-controlled genes, which in turn regulate metabolic pathways and several 14 
physiological processes, including metabolism, development and immunity. In consequence, 15 
loss-of-function studies both in vitro and in vivo support the REV-ERB key role in lipid 16 
metabolism, regulation of plasma glucose levels (Delezie et al., 2012; Solt et al., 2012) as well 17 
as in the oxidative capacity of skeletal muscle and mitochondrial biogenesis (Woldt et al., 2013). 18 
The development and characterization of pyrrole derivates SR9009 and SR9011 (Solt et al., 19 
2012) as specific REV-ERB agonists opened up the possibility of targeting these receptors to 20 
treat several circadian disorders, including metabolic diseases (obesity, dyslipidemia and glucose 21 
intolerance) (Carla B. Green, Takahashi and Bass, 2008; Bass and Takahashi, 2010; Bass, 2012; 22 
Eckel-Mahan and Sassone-Corsi, 2013; Gamble and Young, 2013), sleep disorders (Solt et al., 23 
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2012) and cancer (Sulli et al., 2018). Indeed, pharmacological modulation of circadian rhythms 1 
by these agonists affects tumor cell viability by restraining pathways that are aberrantly activated 2 
in cancer (Sulli et al., 2018). Consistent with the range of metabolic effects noted in REV-ERBα-3 
null mice, pharmacological activation of REV-ERB with SR9009 and SR9011 had additional 4 
metabolic effects in mice including weight loss in diet-induced obese mice, events associated 5 
with an increase in energy expenditure without alterations in locomotor behavior or food intake 6 
(Solt et al., 2012). Taking into account the role of REV-ERBs on lipid, glucose and energetic 7 
metabolism regulation and the high metabolic demands of cancer cells, we postulated that a 8 
pharmacological modulation of circadian components repressors such as REV-ERBs could alter 9 
metabolic pathways that compromise cancer cell survival.  10 
Although disruption of the biological clock altering metabolic pathways can lead to diverse 11 
pathologies, little is known about the temporal regulation of cellular metabolism in tumor cells. 12 
Glioblastoma multiforme (GBM) is the most aggressive human brain tumor characterized by the 13 
aberrant proliferation growth of glial-like tumor cells. In this connection, the human 14 
glioblastoma T98G cells constitute an appropriate cancer cell model to investigate the tumor-15 
intrinsic circadian clock. In our previous work, we found that proliferating T98G cells contain a 16 
functional intrinsic oscillator that controls diverse metabolic processes including lipid 17 
metabolism, levels of reactive oxygen species (ROS), peroxiredoxin oxidation cycles and 18 
susceptibility to treatment with the proteasome inhibitor bortezomib (BOR) (Wagner et al., 19 
2018).  20 
Here we investigated the effects of SR9009 treatment in T98G cell cultures and compared it with 21 
BOR treatment assessing cell viability, differential time responses to chemotherapy after 22 
synchronization with DEX and metabolic processes involving ROS and LD levels In addition, 23 
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we extended these studies to HepG2 cells, a non-neuronal tumor cell line derived from human 1 
liver hepatocellular carcinoma. 2 
 3 
 4 
Material and Methods 5 
Cell Cultures 6 
T98G cells are derived from the human GBM (ATCC, cat. No. CRl-1690, RRUD: CVCL-0556, 7 
Manassas, VA, USA) and tested positive for glial cell markers and negative for mycoplasma 8 
contamination. HepG2 cells (ATCC Cat# HB-8065, RRID: CVCL0027) are derived from the 9 
human hepatocellular carcinoma. Both cell lines were grown in DMEM (Gibco, BRL, 10 
Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS (fetal bovine serum) according to 11 
(Portal, Ferrero and Caputto, 2007) at 37°C and 5% CO2.  12 
 13 
SR9009 treatment and determination of cell viability by MTT assay 14 
Cells were plated in 96-well plates at a density of 1 × 104 and were allowed to attach overnight at 15 
37°C. Cultured cells were incubated with DMSO (vehicle) or REV-ERB agonist (SR9009) at 16 
different concentrations (10, 20 and 40 µM) and incubation time (24, 48 and 72 h). After 17 
incubation, 10 μL of MTT reagent (5 mg/mL; Sigma) were added to each well, and plates were 18 
further incubated for 2 h at 37°C as described (Vlachostergios et al., 2013). Then, 100 μL of 19 
DMSO: isopropanol (1:1, v/v) was added to each well followed by incubation for a few min at 20 
room temperature protected from light. Samples were analyzed at a wavelength of 570 nm with a 21 
reference at 650 nm in an Epoch Microplate Spectrophotometer. Vehicle-treated cells (DMSO) 22 
were considered as 100 % of viability.  23 
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In other series of experiments, 5 × 103 HepG2 cells were allowed to attach overnight at 37°C in a 1 
96-well plate. Cultured cells were incubated with DMSO (vehicle) or REV-ERB agonist 2 
(SR9009) at different concentrations (5, 10, 20 and 40 µM) for 96 h. Then, cell viability was 3 
analyzed by MTT assay considering vehicle-treated cells (DMSO) as 100 % of viability.  4 
 5 
SR9009 treatment of T98G cells and determination of cell viability by alamarBlue assay 6 
Cells were plated in 96-well plates at the density of 1.5 × 103 and allowed to attach overnight at 7 
37°C. Cultured cells were incubated with DMSO (vehicle) or REV-ERB agonist (SR9009) at 8 
final concentration of 20 µM for 48 or 72 h. After incubation, 10 μL of alamarBlue reagent 9 
(Invitrogen) were added to each well (final volume: 100 μl in 96-well plates) and plates were 10 
further incubated for 3 h at 37°C protected from light. Fluorescence intensity was analyzed at an 11 
excitation wavelength of 540-570 nm and fluorescence emission reads at 580-610 nm in a Biotek 12 
microplate reader. Vehicle-treated cells (DMSO) were considered as 100 % of viability.  13 
 14 
Differential temporal susceptibility to SR9009 or Bortezomib treatment  15 
T98G cells were plated in 96-well plates at the density of 1x104 and allowed to attach overnight 16 
in a CO2 incubator at 37 °C. Cell cultures were synchronized by a 20-min shock with 100 nM 17 
DEX and treated with SR9009 (20 μM 48 h) or BOR (500 nM 36 h) (Comba et al., 2019) at 18 
different times post-synchronization. After incubation, cell viability was determined by MTT 19 
assay as described above and analyzed at 570 nm with a reference at 650 nm in an Epoch 20 





Combined chemotherapeutic treatments on T98G cells 1 
In other series of experiment, T98G cells were treated with both drugs together to evaluate 2 
synergism between them. For this, T98G cells were synchronized by a 20 min-shock with 100 3 
nM DEX at 37°C and maintained in 5% FBS-DMEM. Cells were treated with different drug 4 
concentrations alone or in combination as follows: BOR (50 or 500 nM), SR9009 (10 or 20 μM) 5 
BOR (50 nM) + SR9009 (10 μM) or BOR (500 nM) + SR9009 (20 μM), 18 h post-6 
synchronization, and incubated for 36 h at 37°C. Cell viability was analyzed by MTT assay as 7 
described above. Vehicle-treated cells (DMSO) were considered as 100% of viability. 8 
 9 
Cell cycle progression analysis in SR9009-treated T98G cells 10 
T98G cells incubated with DMSO (vehicle) or SR9009 (20 µM) were arrested in serum-free 11 
DMEM for 36 h. Then, the medium was removed and either vehicle or SR9009-treated cells 12 
were stimulated with 20% serum for 16 h in the presence of DMSO or SR9009, respectively. 13 
Lastly, cells harvested by trypsinization were washed in cold PBS and fixed with cold 70% 14 
ethanol at 20°C for at least 24 h. Cell pellets were resuspended in 150 μL of staining solution 15 
(PBS containing 50 μg/mL propidium iodide and 10 μg RNAse A) as reported (Acosta-16 
Rodríguez et al., 2013). Cell cycle analysis was performed with 50,000 cells on a flow cytometer 17 
(DB Bioscience). The analysis program used was FlowJo software (Verity Software House, 18 
Topsham, Maine, USA).  19 
 20 
Redox State in SR9009-treated cells 21 
Redox state was analyzed in T98G cells incubated with SR9009 (20 µM, 48 h) or BOR (500 nM 22 
24 h) and in SR9009-treated-HepG2 cells (40 µM, 48 h). Briefly, the culture medium was 23 
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removed and cells were washed with cold PBS 1X and harvested by trypsinization. Then, cells 1 
were incubated with 2,7-dichlorodihydrofluorescein diacetate at 2 μM final concentration for 40 2 
min at 37 °C, washed twice with PBS 1X, and the fluorescence intensity was measured by flow 3 
cytometry at 530 nm when the sample was excited at 485 nm (Eruslanov and Kusmartsev, 2010). 4 
Cells without the fluorescent indicator were used as negative control and propidium iodide (50 5 
g/mL) staining was used to discriminate viable cells. FlowJo software was used to analyze 6 
fluorescence intensity (Verity Software House, Topsham, Maine, USA).  7 
 8 
Determination of lipid droplets on cells treated with SR9009 or BOR. 9 
T98G cells were incubated with SR9009 (20 µM, 48 h) or BOR (500 nM, 24 h) and LDs levels 10 
were analyzed by confocal microscopy and flow cytometry. For microscopy visualization, 11 
cultured cells were fixed for 15 min in 4% paraformaldehyde in PBS and washed twice with PBS 12 
1X. Then, cells were incubated with Nile Red (1 µg/mL, Sigma) for 15 min at room temperature 13 
protected from light. Coverslips were finally washed thoroughly and visualized by confocal 14 
microscopy (FV1200; Olympus, Tokyo, Japan). Cellular nuclei were visualized by DAPI 15 
staining. Average size quantification of LD was carried out with ImageJ software. 16 
For flow cytometry analysis, either control or treated cells were harvested by trypsinization and 17 
washed twice with PBS 1X. Cell pellets were resuspended in 200 µl of PBS containing 1µg/mL 18 
Nile Red and incubated for 15 min at room temperature protected from light. Then, cells were 19 
washed twice with PBS 1X and the fluorescence intensity was measured by flow cytometry 20 
(BD LSRFortessa™ cell analyzer) with 575/26 filter. A negative control including cells without 21 
the fluorescent indicator was used.  FlowJo software was used to analyze fluorescence intensity.  22 
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HepG2 cells were treated with SR9009 (10 or 40 M for 96 h) and LDs content was assessed by 1 
Nile Red (1 µg/mL) staining as described above. Average size and area of LDs were performed 2 
by the ImageJ software. Cellular nuclei were visualized by DAPI staining. 3 
 4 
Immunocytochemistry 5 
ICC was performed as described (Morera, Díaz and Guido, 2016). Briefly, cultured cells were 6 
fixed for 15 min in 4% paraformaldehyde in PBS and 10 min in methanol. Coverslips were 7 
washed in PBS, treated with blocking buffer (PBS supplemented with 0.1% BSA, 0.1% Tween 8 
20, and 0.1% glycine) and incubated overnight with primary antibodies (Table 1) at 4°C. 9 
Coverslips were washed three times and incubated with goat anti-rabbit IgG (Jackson 549 10 
antibody 1:1000) or goat anti-mousse IgG (Jackson 488 antibody 1:1000) for 1 h at room 11 
temperature. Coverslips were finally washed thoroughly and visualized by confocal microscopy 12 
(FV1200; Olympus, Tokyo, Japan). Cellular nuclei were visualized by DAPI staining. 13 
 14 
Statistics  15 
Statistical analyses involved a one- or two-way analysis of variance (ANOVA) to test the time or 16 
drug treatment effects and Kruskal-Wallis (K-W) when the normality of residuals was infringed 17 
residuals did not show normality. Pairwise comparisons involved the Student t-test or Bonferroni 18 
when appropriate. Data are expressed as mean ± SEM. In all cases significance was considered 19 
at p<0.05. 20 
 21 
Table 1: Antibody List.  22 





Mouse Millipore Cat# MAB302, RID:AB_2110656 1:100 
VIMENTIN Mouse 
Sigma-Aldrich Cat# V5255, 
RRID:AB_477625) 
1:750 
GFAP Rabbit Agilent Cat# Z0334, RRID:AB_10013382 1:250 
REV-ERBα Mouse 








Here we investigated SR9009 effects and compared it with BOR, a proteasome inhibitor 6 
previously used, on T98G cell viability, differential chemotherapy time responses and underlying 7 
metabolic processes concerning ROS and LDs levels. Also, we extended these studies to HepG2 8 
cells to evaluate SR9009 effects on cell viability, LDs and ROS levels. 9 
 10 
Characterization of T98G cells and susceptibility to SR9009 treatment 11 
Human T98G cells kept in culture under proliferative conditions (5% FBS-DMEM) expressed 12 
typical markers for glial cells such as Vimentin, Glutamine Synthase and GFAP (Fig.1 A-C) as 13 
well as the circadian clock component REV-ERB (Fig. 1 D). In addition, T98G cells were 14 
previously shown to express the clock protein PER1 and display temporal fluctuations on PER1-15 
like protein by immunocytochemistry with highest levels at 18 and 24 h after synchronization 16 
(Wagner et al., 2018).  [insert Figure 1] 17 
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 When cells were treated with the REV-ERB specific agonist SR9009 at different concentrations 1 
going from 10 to 40 μM for 24, 48 or 72 h (Figs. 1 and 2 a), significant effects on cell 2 
morphology (Fig, 1 E-F) and reduction in cell viability were observed at final concentrations of 3 
20 and 40 μM for 48 and 72 h (Fig. 2 a) as compared with vehicle-treated controls (p < 0.0001 4 
by K-W). It is noteworthy that a significant decrease in cell viability is observed after SR9009 5 
treatment with only  20 % of cells remaining viable under the tested conditions (20 and 40 µM 6 
of SR9009 for 72 h). Moreover, a significant reduction in cell viability was also observed on 7 
SR9009-treated HepG2 cells (40 μM for 96 h) (p< 0.0002 by K-W) (Fig. 2 b). [insert Figure 2] 8 
In addition, to further support these observations, cell viability was also analyzed by alamarBlue 9 
assay after T98G cells incubation with SR9009 (20 μM) for 48 or 72 h at 37°C. Similar to 10 
findings found for MTT assay, a significant reduction in cell viability was observed when cells 11 
were treated with   SR9009 (20 μM) for 48 or 72 h (p < 0.0005 by ANOVA) (Suppl. Fig. 1). 12 
[insert Suppl. Figure 1] 13 
 14 
Differential temporal susceptibility to SR9009 treatment  15 
T98G cells were synchronized with DEX (100 nM) and treated with SR9009 (20 μM) for 48 h at 16 
different times post-synchronization along 36 h. Cell viability analyzed by MTT assay in 17 
SR9009-treated cells was compared with vehicle-treated cells and showed a significant temporal 18 
effect of drug treatment, with the lowest levels of viability during a time-window going from 18 19 
to 30 h after synchronization. The statistical analysis clearly revealed a significant effect of 20 
treatment versus time (p < 0.0041 by K-W) (Fig.3 a). These observations agree with those 21 
previously found in synchronized T98G cells treated with BOR (500 nM) for 36 h (Wagner et al 22 
13 
 
2018) exhibiting the lowest cell viability in a time window going from 12 to 24 h post-1 
synchronization (p < 0.0007 by K-W) (Fig. 3 b). [insert Figure 3] 2 
 3 
Effects of SR9009 treatment on T98G cells cell cycle progression. 4 
To further investigate whether SR9009 treatment alters cell cycle progression, T98G cells 5 
were arrested in serum-free medium for 36 h in the presence of DMSO (vehicle) or SR9009 (20 6 
μM). Then, medium was removed and either control or treated cells were stimulated with 20% 7 
serum for 16 h in the presence of DMSO or SR9009 respectively. Flow cytometry analysis 8 
showed a higher proportion of SR9009-treated cells ( 58%) in G0/G1 phases after serum 9 
stimulation as compared with vehicle-treated cells ( 43%) (p < 0.0053 by t-Test). By contrast, 10 
vehicle-treated cells showed a higher proportion of cells in S phase ( 40%) with respect to 11 
SR9009-treated cells ( 22%) (p < 0.0121 by t-Test) (Fig. 4 a-c). [insert Figure 4]. 12 
 13 
SR9009 effect on redox and lipid metabolism  14 
In order to investigate whether oxidative stress could be involved in the effects of SR9009 15 
treatment in cell viability, we analyzed ROS levels and compared it with those in BOR-treated 16 
cells. To this end, T98G cells were incubated with SR9009 (20 μM) for 48 h and the redox state 17 
was analyzed by incubation with 2′,7′-dichlorodihydrofluorescein diacetate (2 μM) for 40 min at 18 
37°C. When fluorescence intensity was measured by flow cytometry, a significant reduction in 19 
ROS levels was seen in SR9009-treated cells as compared with vehicle-treated controls (p < 20 
0.007 by t-Test) (Fig. 5 a). In contrast, T98G cells previously incubated with BOR (500 nM) for 21 
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24 h showed higher levels of ROS with respect to those in control cells (p < 0.04 by t-Test) (Fig. 1 
5 b).  [insert Figure 5]. Moreover, SR9009 (40 μM) treatment in HepG2 cells for 96 h also 2 
showed a significant decreased on ROS levels as compared with vehicle-treated cells (p < 0.0001 3 
by ANOVA) (Fig. 7 f).   4 
In other series of experiments, we proceeded to evaluate LDs levels after treatments with 5 
SR9009 or BOR. LDs are cytoplasmic organelles responsible for storing the excess of cellular 6 
lipids (Farese and Walther, 2009; Beller et al., 2010; Brasaemle and Wolins, 2012) and mainly 7 
involved in energy storage. 8 
In order to investigate whether SR9009 treatment alters lipid accumulation in LDs, we used Nile 9 
Red which is intensely fluorescent and can serve as a sensitive vital stain for the detection of 10 
cytoplasmic LDs. To this end, SR9009 or BOR-treated cells were stained with Nile Red and LDs 11 
visualized by confocal microscopy and flow cytometry. First, LDs in SR9009-treated cells 12 
showed a higher average size as compared with vehicle-treated cells (p < 0.003 by t-test) (Fig. 6 13 
a-c). In agreement with this, a higher fluorescence intensity was visualized by flow cytometry 14 
either in SR9009 and BOR-treated cells as compared with untreated cells (p < 0.002 and p < 15 
0.025, respectively by t-test) (Fig. 6 d-f). [insert Figure 6].  16 
Similar results were observed in HepG2 cells exhibiting a higher average size of LDs after 17 
SR9009 treatment (10 and 40 μM for 96 h) as compared with control cells (p < 0.0001 by 18 
ANOVA) (Fig. 7 a-d). Moreover, the percentage of LDs area related to the total area of each cell 19 
was increased after drug treatment (40 μM for 96 h) (Fig. 7 e) (p < 0.0001 by K-W).  20 
 21 
Combined chemotherapeutic treatments on T98G cells 22 
15 
 
Even though SR9009 or BOR treatments showed marked effects in cell viability, we explored 1 
whether the combination of these two drugs could improve chemotherapeutic effects. To this 2 
end, T98G cells were treated with BOR (50 or 500 nM), SR9009 (10 or 20 μM) and their 3 
combination (BOR 50 nM + SR9009 10 μM or BOR 500 nM + SR9009 20 μM) at 18 h post-4 
synchronization for 36 h and cell viability was analyzed by MTT assay. When BOR or SR9009 5 
treatments were given alone at low doses still a 60% of cells remained viable however, the 6 
combination of these compounds at low concentrations (BOR 50 nM + SR9009 10 μM), reduced 7 
cell viability to 28% (Fig. 8 a) as compared with each drug alone (p < 0.003 by K-W). In 8 
addition, at high drug concentration, 28% and 34% of cells remained viable, after BOR or 9 
SR9009 treatment respectively; whereas, when both drugs were applied together to T98G cells at 10 
high doses, a significant reduction in cell viability was observed and only 17% of cells were still 11 
viable (p < 0.0001 by ANOVA) (Fig. 8 b). The results clearly demonstrated an important 12 
synergic effect of drug combination. [insert Figure 8].   13 
 14 
Discussion 15 
 Our results demonstrated that the pharmacological modulation of the tumor intrinsic 16 
clock by a specific REV-ERB agonist severely affected tumor cell metabolism and promoted 17 
cytotoxic effects on glioma and hepatocellular carcinoma cells. These observations showed for 18 
the first time that glioblastoma cells can be treated pharmacologically under a time-dependent 19 
therapy through the modulation of the circadian clock involving the control of metabolism to 20 
achieve the highest antitumor treatment efficacy. SR9009 treatment altered the typical glial cell 21 
morphology (Fig. 1), cell viability (Figs. 2-3) and metabolism by increasing levels of LDs and 22 
decreasing those for ROS (Figs. 5-6). Moreover, the treatment with SR9009 further potentiates 23 
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the effect of BOR (Fig. 8), which was previously shown to have strong effects on cell viability of 1 
glioma cells under a circadian chronotherapy (Wagner et al., 2018). However, the mechanisms 2 
used for these two chemotherapeutic agents seemed to be different in terms that BOR inhibits the 3 
proteasome function while SR9009 acts on the clock-related cellular metabolism; nevertheless, 4 
both of them were shown to substantially elevate levels of LDs (Fig. 6-7). Also, and remarkably, 5 
both agents exhibited a clear time window of highest cellular susceptibility to treatment with 6 
maximal effects from 12-18 to 24 h after DEX synchronization (Fig. 3 and Wagner et al., 2018). 7 
Moreover, when the circadian clock was disturbed by Bmal1 knock-down a circadian variation in 8 
BOR treatment susceptibility was still observed but with a different phase and amplitude than 9 
that described in wild-type T98G cells (Wagner et al., 2018). In previous reports, proliferative 10 
T98G cells were synchronized by DEX which is commonly used in GBM patients, to reduce 11 
inflammation or as a chemotherapy adjuvant; in fact, glucocorticoids can inhibit cancer cell 12 
proliferation by limiting the number of cells in S phase and additionally increasing the time spent 13 
in the G1 phase (Kiessling et al., 2017; Wagner et al., 2018).   14 
Results shown in Fig. 4 strongly indicate that this REV-ERB agonist also affected the cell cycle 15 
progression since  60% of SR9009-treated cells remained arrested in G0/G1 phases as compared 16 
with control cells after serum stimulation. It is known that GBM is the most aggressive brain 17 
tumor and that the development of more effective anti-cancer strategies can be useful for clinical 18 
use. In this regard, the combination of both agents applied at the right temporal window and at 19 
lower individual doses, as seen in glioma cell cultures can offer an additional opportunity to 20 
effectively treat cancer cells in a synergic manner. 21 
Circadian rhythms are intricately linked to the regulation of metabolism, and genetic 22 
perturbations of core clock genes lead to a range of abnormal metabolic phenotypes in mice, 23 
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including obesity, dyslipidemia and glucose intolerance (Carla B Green, Takahashi and Bass, 1 
2008; Bass and Takahashi, 2010; Bass, 2012; Eckel-Mahan and Sassone-Corsi, 2013; Gamble 2 
and Young, 2013). In this connection, modern life including hyper-caloric diets, sedentary 3 
routines, artificial illumination at night, the reduction in sleep hours, shiftwork and jetlag among 4 
others, may cause circadian disorganization promoting higher cancer risk and metabolic 5 
disorders. 6 
RORs and REV-ERBs play key roles in the regulation of metabolic pathways linking the core 7 
circadian oscillator to the regulation of clock-controlled genes. Loss-of-function studies both in 8 
vitro and in vivo demonstrate that REV-ERBs have a crucial role in lipid metabolism as seen in 9 
REV-ERBα-null mice exhibiting dyslipidemia with elevated levels of very-low-density 10 
lipoprotein, triglyceride and increased serum levels of apolipoprotein C3 (Raspé et al., 2001, 11 
2002). In this connection, lipids are stored in LDs as neutral lipids, namely free fatty acids and 12 
cholesterols that are enzymatically converted to triacylglycerol and cholesteryl esters, 13 
respectively, and then incorporated into LDs  (Farese and Walther, 2009; Beller et al., 2010; 14 
Brasaemle and Wolins, 2012). These organelles are not restricted to energy storage but also 15 
participate in stress protection, protein sequestration, membrane trafficking and signaling having 16 
a great impact on physiology, health and disease (Welte & Gould, 2017). Nevertheless, the 17 
treatment with SR9009 significantly increased average size of LDs in T98G as well as in HepG2 18 
cells. These observations agreed with a significant deficiency in surfactant phospholipids such as 19 
phosphatidylcholine or accumulation of phosphatidic acid under SR9009 treatment increasing 20 
LD fusion or coalescence (Guo et al., 2008; Fei et al., 2011). In fact, REV-ERB agonists were 21 
shown to be inhibitors of autophagy and de novo lipogenesis, with selective activity towards 22 
malignant and benign neoplasms; the accumulation of LDs may be due to an uptake and 23 
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accumulation of fatty acids (Bensaad et al., 2014) and not to de novo synthesis of lipids since the 1 
expression of the two key enzymes fatty acid synthase and stearoyl- CoA desaturase 1 involved 2 
in de novo lipogenesis were decreased after REV-ERBs agonist treatment (Sulli et al., 2018).  3 
Interestingly, autophagy contributes to the intracellular catabolism of lipids in hepatocytes, 4 
fibroblasts (Singh et al., 2009) and neurons (Martinez-Vicente et al., 2010) while  the 5 
pharmacologic or genetic inhibition of autophagy in hepatocytes leads to reduced rates of β-6 
oxidation and marked lipid accumulation in cytosolic LDs (Singh et al., 2009).  Autophagy is an 7 
ATP dependent process (Meijer and Codogno, 2004), and autophagy inhibition reduces 8 
mitochondrial β-oxidation rates (Singh et al., 2009; Heaton et al., 2010) and energy production. 9 
Autophagy-deficient stellate cells as shown in hepatocytes may be unable to process LDs by acid 10 
lipases, resulting in LDs accumulation and decreased free fatty acid availability, leading to 11 
decreased mitochondrial β-oxidation.   12 
Moreover, BOR treatment at low concentrations (5 nM) was shown to cause lipid accumulation 13 
associated with mitochondrial impairment (Guglielmi et al., 2017). The mechanisms used for 14 
these two chemotherapeutic agents seemed to be different concerning the redox state since BOR 15 
induced ROS levels while SR9009-treated cells showed decreased levels of them. Even though, 16 
the sequence of events leading to apoptosis following proteasome inhibition by BOR is unclear, 17 
byproducts of normal cellular oxidative processes such as ROS have been suggested as 18 
regulating the process involved in the initiation of apoptotic signaling. Tan and coworkers (1998) 19 
previously showed that an increase in ROS generation induces cytochrome c release from 20 
mitochondria (Tan et al., 1998). Increased levels of ROS in BOR-treated cells were also 21 
observed in colorectal (Kim, 2012) and human H460 non-small cell lung cancer cells (Ling et 22 
19 
 
al., 2003) as well as in human leukemia cells (Yu et al., 2004). Conversely, SR9009-treated cells 1 
showed decreased ROS levels as compared with untreated cells for both tumor cell lines. These 2 
results support the idea proposed by Sulli and colleagues (2018) suggesting that excessive ROS 3 
production is not involved in the enhanced sensitivity of cancer cells to SR9009 treatment (Sulli 4 
et al., 2018). 5 
Overall, the pharmacological activation of REV-ERBs by the pyrrole derivative SR9009 as 6 
specific agonist (Solt et al., 2012) has been clearly shown to affect tumor cell viability restricting 7 
abnormally activated pathways as demonstrated on different tumor cell types, namely brain, 8 
leukemia, breast, colon and melanoma (Sulli et al., 2018). Therefore, and in agreement with 9 
these previously reported observations the antitumor activity of SR9009 was clearly evidenced in 10 
T98G and HepG2 cells displaying significant cytotoxic effects and pronounced metabolic 11 
changes. 12 
 13 
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Figure Legends 1 
Figure 1: Protein expression in T98G cells by immunocytochemistry and SR9009 treatment 2 
effect. T98G cells express typical markers of glial cells such as vimentin (A - green) and 3 
glutamine synthase (GS; B - green) visualized by immunofluorescence with specific primary 4 
antibodies and confocal microscopy. T98G cells were incubated with vehicle (DMSO) or 5 
SR9009 (20 μM) for 48 h and immunolabeled for GFAP (C, E - red) or REV-ERBα (D, F - 6 
green) with specific primary antibodies and confocal microscopy; insets on the right further 7 
magnified a single cell in both conditions (DMSO and SR9009 treatment) . See Methods for 8 
further detail. Scale bar = 10 μm 9 
 10 
Figure 2: Cell susceptibility to SR9009 treatment in cultures of T98G (a) and HepG2 (b) 11 
cells. a. T98G cells were treated with different SR9009 concentrations (10, 20 and 40 µM) for 12 
24, 48 or 72 h at 37°C. Cell viability analyzed by MTT assay revealed a significant effect of 13 
SR9009 when T98G cells were incubated with a final concentration of 20 µM for 48 h (*p < 0.05 14 
by K-W) and 20 µM for 72 h and 40 µM for 48 or 72 h (***p < 0.0001 by K-W). The results are 15 
mean ± SEM of two independent experiments (n= 5-6/group), b. HepG2 cells were treated with 16 
different SR9009 concentrations (5, 10, 20 and 40 µM) for 96 h. A significant reduction in cell 17 
viability was observed when HepG2 cells were treated with 40 µM for 96 h as compared with 18 
untreated cells (**p < 0.0002 by K-W). The results are mean ± SEM of two independent 19 
experiments (n= 5-6/group).  20 
 21 
Figure 3: Temporal response to SR9009 (a) or BOR (b) treatment in T98G cells. a. Cells 22 
were synchronized with dexamethasone (DEX, 100 nM), and SR9009 was added to a final 23 
26 
 
concentration of 20 μM at different times post-synchronization for 48 h. Cell viability was 1 
analyzed by MTT assay as described in Materials and Methods. A significant temporal variation 2 
was observed in levels of T98G cell viability (*p < 0.004 by K-W). The results are mean ± SEM 3 
of three independent experiments (n = 5–6/group). b. DEX-synchronized cells were treated with 4 
BOR (500 nM) for 36 h at different times post-synchronization and cell viability assessed by 5 
MTT assay. A significant time-effect was observed in levels of T98G cell viability (**p < 0.0007 6 
by K-W) as previously observed in Wagner et al (2018). Results are mean ± SEM from one 7 
representative experiment (n = 5-6/group).  8 
 9 
Figure 4: Effects of SR9009 treatment on cell cycle distribution of T98G cells. T98G cells 10 
incubated with DMSO (vehicle) or SR9009 (20 µM) were arrested in serum-free DMEM for 36 11 
h. Then, the medium was removed and either vehicle or treated cells were stimulated with 20% 12 
SFB for 16 h in the presence of DMSO or SR9009 as appropriate. Cell cycle phases were 13 
analyzed by staining with propidium iodide and flow cytometry. Representative cell cycle 14 
distributions are shown in control (a) or SR9009-treated cells (b). c) Quantification of the 15 
percentage of cells in each phase showed a higher proportion of SR9009-treated T98G cells in 16 
G0-G1 phase (G0-G1 *p < 0.0053, S *p < 0.01 by t-test).  The results are mean ± SEM of three 17 
independent experiments (n=4/group). 18 
 19 
Figure 5: ROS levels in T98G cells treated with SR9009 or BOR. T98G cells were treated 20 
either with SR9009 (a, 20 μM 48 h) or BOR (b, 500 nM 24 h) and ROS levels were analyzed 21 
with the fluorescent probe 2,7-dichlorodihydrofluorescein diacetate to a final concentration of 2 22 
27 
 
μM as described in Materials and Methods. Fluorescence intensity was analyzed by flow 1 
cytometry. The results are mean ± SEM of two/three independent experiments (n = 3-5/group). 2 
The statistical analysis revealed a significant effect for SR9009 (**p < 0.001 by t-test) and for 3 
BOR (*p < 0.04 by t-test) as compared with vehicle-treated controls. 4 
 5 
Figure 6: Lipid Droplets levels in T98G cells treated with SR9009 or BOR. T98G cells were 6 
treated either with SR9009 (20 μM, 48 h) (a-d) or BOR (500 nM, 24 h) (e-f) and LDs levels were 7 
analyzed by Nile Red staining. Representative microphotography of LDs observed in vehicle (a) 8 
or SR9009-treated T98G cells (b) stained with Nile Red were visualized by confocal microscopy, 9 
further magnified in the insets on the right. Scale bar=10 μm. c) Histograms showing 10 
Quantification of average size of LDs in SR9009-treated T98G cells. Results revealed a higher 11 
average size of LDs in cells treated with SR9009 (*p < 0.003 by t-test) as compared with 12 
controls. d, f) Histograms showing  Quantification of fluorescence intensity of LDs stained with 13 
Nile Red and analyzed by flow cytometry. In both treatments, results showed a higher 14 
fluorescence intensity when T98G cells were treated with SR9009 (d, *p < 0.002 by t-test) or 15 
BOR (f, *p < 0.025 by t-test) as compared with controls. e) Representative histograms of 16 
fluorescence intensity of LDs analyzed by flow cytometry in BOR-treated cells. Data are mean ± 17 
SEM. The results are mean of three independent experiments (n = 3-5 /group).  18 
 19 
Figure 7: Lipid Droplets and ROS levels in HepG2 cells treated with SR9009. a-c) 20 
Representative microphotographs of Nile Red stained LDs in HepG2 cells treated with the 21 
vehicle (a) or SR9009 (b, 10 μM; c, 40 μM). Scale bar=10 μm. d) Quantification of Histograms 22 
of LDs average size quantification for  on SR9009-treated HepG2 cells that revealed a significant 23 
28 
 
increase as compared with controls (***p < 0.0001 by ANOVA, Bonferroni post hoc). e) 1 
Quantification of Histograms of LDs percentage area quantification for on SR9009-treated 2 
HepG2 cells. A significant increase was observed with 40 μM SR9009 treatment for 96 h (***p 3 
< 0.0001 by K-W). f) Determination of ROS levels by flow cytometry in HepG2 cells treated 4 
with SR9009 (5 and 40 μM for 96 h). A significant reduction was observed at 40 μM SR9009-5 
treated cells as compared with vehicle and 5 and 20 μM  of SR9009 (***p < 0.0001 by ANOVA, 6 
Bonferroni post hoc).  7 
 8 
Figure 8: T98G cell susceptibility to the combined treatment with SR9009 and BOR. T98G 9 
cells treated with BOR (50 or 500 nM), SR9009 (10 or 20 μM) and their combination (BOR 50 10 
nM + SR9009 10 μM or BOR 500 nM + SR9009 20 μM) at 18 h post-synchronization for 36 h. 11 
Cell viability was analyzed by MMT assay and results showed a significant reduction in cell 12 
viability when T98G cells were treated with the combination of drugs (BOR 50 nM + SR9009 10 13 
μM **p<0.003, BOR 500 nM + SR9009 20 μM ***p<0.0001 by K-W) as compared with cells 14 
treated with each drug alone. Data are mean ± SE. The results are mean of three independent 15 
experiments (n = 5-6 /group). 16 
 17 
Supplementary Figure Legends 18 
Suppl. Fig. 1: Cell susceptibility to SR9009 treatment in cultures of T98G cells by 19 
alamarBlue. Cells were treated with SR9009 (20 µM) for 48 or 72 h and cell viability was 20 
analyzed by alamarBlue reagent. A significant effect of the REV-ERB agonist treatment was 21 
29 
 
observed when cells were incubated at a final concentration of 20 µM for 48 and 72 h 1 
(***p<0.0005 by ANOVA, Bonferroni post hoc).  2 
 3 
